Fortress Biotech (FBIO) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.53 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of 67.09%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.27 per share when it actually produced a loss of $0.76, delivering a surprise of -181.48%. Over the last four quarters, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from ____ to _____. Commission File No. 001-35366 FORTRESS BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of I ...

Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights Exhibit 99.1 Emrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled Recent Corporate Highlights1: Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; Checkpoint's lead product, UNLOXCYT™, approved by FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carc ...

Emrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled Monetization Updates In March 2025, our subsidiary Checkpoint entered into an agreement to be acquired by Sun Pharmaceutical Industries Limited (together with its subsidiaries and/or associated companies, "Sun Pharma"). Fortress owns approximately 6.9 million shares (including Class A Common on an as- converted basis) of Checkpoi ...

Fortress Biotech, Inc. (NASDAQ:FBIO) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and CEO Joseph Benesch - CFO Srinivas Sidgiddi - VP, R&D Louis Donati - Director, Market Access Conference Call Participants Thomas Flaten - Lake Street Capital Markets Scott Henry - AGP Brandon Folkes - Rodman & Renshaw Jason Wittes - ROTH Capital Kalpit Patel - B. Riley Securities Operator Ladies and ...

FRANKFURT, Germany and MIAMI, March 17, 2025 (GLOBE NEWSWIRE) -- Partex NV and Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced a strategic collaboration aimed at identifying and evaluating biopharmaceutical compounds using artificial intelligence (AI) for potential acquisition or licensing by Fortress. Partex will deploy its proprietary AI-based drug discovery and development technology platform, which delivers diverse recommendations on alternati ...

WORCESTER, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced the closing of its previously announced public offering, for the issuance and sale of an aggregate of 2,657,807 shares of its common stock (or common stock equivalents in lieu thereof), Series C-1 warrants to purcha ...

WORCESTER, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced the pricing of a public offering of an aggregate of 2,657,807 shares of its common stock (or common stock equivalents in lieu thereof), Series C-1 warrants to purchase up to 2,657,807 shares of common stock and Seri ...

Study is the first randomized, controlled trial examining a vaccine's effectiveness in controlling CMV in recipients of HSCT from vaccinated donors Encouraging pilot study results demonstrated the benefit of vaccinating donors with Triplex to convey protective CMV-specific T cell immunity to allogeneic HSCT recipients at risk for CMV reactivation MIAMI, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), and its majority-owned subsidiary, Helocyte, Inc. ("Helocyte"), today a ...

Reverse Stock Split - Mustang Bio Inc announced a 1-for-50 reverse stock split of its issued and outstanding common stock, effective from January 16, 2025 [1] - The reverse stock split was approved by the Board of Directors and stockholders representing approximately 56% of the voting power on June 27, 2024 [2] - The number of outstanding shares will be reduced from approximately 64.8 million to approximately 1.3 million, with no fractional shares issued and proportional cash payments made instead [3] Compliance and Trading Details - The reverse stock split aims to bring the company into compliance with Nasdaq's $1.00 per share minimum bid price requirement for continued listing [2] - Mustang's common stock will continue to trade on Nasdaq under the symbol "MBIO" with a new CUSIP number of 62818Q302 [3] - VStock Transfer LLC is acting as the exchange and paying agent for the reverse stock split, providing instructions for physical share certificate exchanges [4] Company Overview - Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on developing cell therapies for difficult-to-treat cancers [5] - The company partners with top medical institutions to advance CAR-T therapies and aims to license or acquire technologies for research and development [5] - Mustang was founded by Fortress Biotech Inc and its common stock is registered under the Securities Exchange Act of 1934 [5]